Pharmaceuticals
Telix Files TLX250-CDx (Zircaix®) BLA for Kidney Cancer Imaging
MELBOURNE, Australia and INDIANAPOLIS, Dec. 30, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces that it has submitted its Biologics License Application (BLA) tothe United States (U.S.) Food and Drug Administration (FDA) for TLX250-CDx...
2024-12-30 06:00
3141
Ascentage Pharma to Present at 43rd Annual J.P. Morgan Healthcare Conference
ROCKVILLE, Md. and SUZHOU, China, Dec. 27, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that its Chairman and ...
2024-12-27 09:44
11884
IND Application for a Phase I/II Clinical Study of Anti-HER2 Bispecific ADC Subcutaneous Co-formulation JSKN033 was Approved
SUZHOU, China, Dec. 26, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that a phase I/II clinical trial (Study ID: JSKN033-102) of JSKN033, a high-concentration subcutaneous co-formulation consisting of anti-HER2 bispecific antibody-drug conjugate (ADC) and PD-L1 immune ch...
2024-12-26 17:09
5024
Kickstart 2025 with Expert Holiday Health Tips
KUALA LUMPUR, Malaysia, Dec. 23, 2024 /PRNewswire/ -- As Pantai Hospital Kuala Lumpur (PHKL) celebrates 50 years of excellence in patient care, it's a moment to reflect on how small, proactive steps can make a significant difference to your health. The holiday season is a time of joy, but it also...
2024-12-23 15:21
4870
SCG Cell Therapy partners A*STAR to accelerate RNA-based therapeutic development in Singapore
* SCG Cell Therapy signed a Memorandum of Understanding (MoU) with A*STAR Bioprocessing Technology Institute (A*STAR BTI) and Nucleic Acid Therapeutics Initiative (NATi) to advance ribonucleic acid (RNA)-based therapeutic manufacturing process development and clinical translation. * The parti...
2024-12-23 09:00
3516
Macrogen Consortium win tender for National Bio Big Data Project
Illumina is proud to be selected as sequencing technology partner to the Macrogen Consortium. SEOUL, South Korea, Dec. 23, 2024 /PRNewswire/ -- Macrogen a global healthcare company that specializes in precision medicine and Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and arra...
2024-12-23 08:00
3575
Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration
SAN FRANCISCO and SUZHOU, China, Dec. 20, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune...
2024-12-20 20:20
6981
Telix Manufacturing Solutions, Brussels South Update: Cyclotron Installation Complete
MELBOURNE, Australia and INDIANAPOLIS, Dec. 19, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces that it has completed the installation of two new cyclotrons at Telix Manufacturing Solutions (TMS) in Brussels South,Belgium, facilita...
2024-12-19 17:02
3582
Pharus Diagnostics LLC Announces Validation of a Laboratory-Developed Test for Early Pancreatic Cancer Detection
LOS ANGELES, Dec. 19, 2024 /PRNewswire/ -- Pharus Diagnostics LLC. (PharusDx), an innovator in non-invasive diagnostic tests, today announced a significant step forward in the fight against pancreatic cancer. The company is announcing availability of its OncoSweep™ Pancreas Spotlight, a liquid bi...
2024-12-19 01:00
3293
Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Preclinical Model
* In a head-to-head diet-induced obese (DIO) mouse study, ASC47 low dose combination 1 (ASC47, 3 mg/kg, subcutaneous(SQ), once every four weeks plus semaglutide, 30 nmol/kg, SQ, once daily), demonstrated superior weight loss compared to semaglutide monotherapy (30 nmol/kg, SQ, once daily), show...
2024-12-18 21:43
4042
Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 head-to-head with Tirzepatide clinical trial)
BEIJING and BRIDGEWATER, N.J., Dec. 18, 2024 /PRNewswire/ -- Gan & Lee Pharmaceuticals (Gan & Lee, Shanghai Stock Exchange: 603087.SH), is pleased to announce that the Food and Drug Administration (" FDA ") has cleared the Investigational New Drug (IND) application for GZR18 Injection to conduct ...
2024-12-18 19:34
3664
Fosun International Awarded TVB's Highest Honor "Outstanding ESG Award"
HONG KONG, Dec. 18, 2024 /PRNewswire/ -- On 13 December 2024, the "TVB ESG Awards" ceremony, hosted by Television Broadcasts Limited (hereinafter referred to as "TVB"), was held at the Hong Kong Convention and Exhibition Centre. Fosun International was honored with the highest accolade, the "Outs...
2024-12-18 11:43
2786
Neurizon Files IND Application to Support HEALEY ALS Platform Trial
Highlights: * IND application submission to the U.S. Food and Drug Administration (FDA) is a pivotal step in initiating a Phase 2/3 clinical study for NUZ-001 * The IND is a comprehensive dossier of information, including animal and human studies, pharmacokinetic analyses, toxicology studies,...
2024-12-18 10:59
2869
Everest Medicines Announces the First Prescription of VELSIPITY® in the Greater Bay Area, Officially Benefiting Mainland China Patients
SHANGHAI, Dec. 18, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that the first prescription for VELSI...
2024-12-18 08:00
2530
Xinhua Silk Road: Why is Pien Tze Huang selected as one of China's brands favored by foreigners in 2024
BEIJING, Dec. 17, 2024 /PRNewswire/ -- Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. (Pien Tze Huang), a time-honored Chinese enterprise mainly engaging in pharmaceutical manufacturing, was selected as one of China's brands favored by foreigners in 2024 at the 2024 China Brand Day gala held i...
2024-12-17 20:40
2841
Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY® by the National Medical Products Administration of China for the Treatment of Moderately to Severely Active Ulcerative Colitis
SHANGHAI, Dec. 17, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that the National Medical Products Ad...
2024-12-17 11:48
3278
Menarini Group announces Positive Topline Data from Pivotal Phase 3 BROADWAY & TANDEM Clinical Trials Evaluating Obicetrapib and the Fixed-Dose Combination Obicetrapib with Ezetimibe 10 mg
– Both pivotal studies achieved primary endpoints of LS mean reduction in LDL-C on top of maximally tolerated lipid-modifying therapies with high statistical significance (p<0.0001) – Approximately 50% of patients in BROADWAY (Obicetrapib monotherapy) and over 70% of patients in TANDEM (Fixed Do...
2024-12-16 22:08
2772
HiRO Forges Strategic Partnership with CHA University Bundang Medical Center in South Korea
SEOUL, South Korea, Dec. 16, 2024 /PRNewswire/ -- Harvest Integrated Research Organization (HiRO), a boutique globalclinical research organization (CRO) providing cross-border clinical trial solutions, proudly announces the signing of a Memorandum of Understanding (MOU) with CHA University Bundan...
2024-12-16 10:30
3428
Innovent and Lilly Expand Collaboration Through Agreement on Commercialization Rights for Jaypirca® (pirtobrutinib) in Mainland China
SAN FRANCISCO and SUZHOU, China, Dec. 16, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic...
2024-12-16 07:55
3939
Bushu Pharma Applauded by Frost & Sullivan for Offering Customer Value in APAC CDMO Industry Through Consistent Quality Assurance, On-time Delivery, Sustainability, and Competitive Costs
Bushu Pharma's ongoing investments and efforts offer customers state-of-the-art capabilities, increased capacity, and innovative solutions, providing top-tier pharmaceutical manufacturing and supply chain management services. SAN ANTONIO, Dec. 15, 2024 /PRNewswire/ -- Frost & Sullivan researched ...
2024-12-15 13:30
2423
Week's Top Stories
Most Reposted
Visa partners with Laufey to spread the magic of travel in Asia Pacific; to be Official Payment Partner for Laufey: A Matter of Time Tour
[Picked up by 309 media titles]
2026-03-04 12:35
SMU and Fudan Launch Region's First Tech-Focused DBA
[Picked up by 300 media titles]
2026-03-02 09:15Klook's Spring Readiness Index shows how Asia's travelers are preparing for spring travel across Japan, South Korea, and Mainland China
[Picked up by 290 media titles]
2026-03-03 15:49
Infobip is set to launch AgentOS to orchestrate autonomous AI-driven customer journeys at scale
[Picked up by 290 media titles]
2026-03-02 09:00
COL and NASDAQ-Listed BeLive Holdings Unveil World's First "Microdrama in a Box" in Headline Hong Kong FILMART 2026 Launch
[Picked up by 285 media titles]
2026-03-05 17:14
Most Read
COLUMBIA ASIA HOSPITAL BUKIT JALIL LAUNCHES NEW CATH LAB TO STRENGTHEN HEART CARE SERVICES
2026-03-02 14:24
9734
